Biomarker ID | 880 |
PMID | 22355332 |
Year | 2012 |
Biomarker | Alpha-2 HS-glycoprotien chain B + Afamin + Fibronectin 1 |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Downregulated [Alpha-2 HS-glycoprotien chain B (1.9 fold) + Afamin (1.9 fold)+ Fibronectin 1 (2.1 fold)] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Progressing Vs Metastatic Prostate Cancer |
Type of Biomarker | Prognostic |
Cohort | Samples were collected from 4 groups with 5 samples each:benign prostatic hyperplasia (BPH); ii) localised cancer with no evidence of progression, (non-progressing) (iii) localised cancer with evidence of biochemical progression, (progressin), and (iv) bone metastasis at presentation (metastatic). |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p ≤0.01 |
Method Used | 4-plex iTRAQ |
Clinical | No |
Remarks | represents biomarkers assessed individualy, + represents biomarkers assessed as a pair or panel |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | AHSG, AFM, FN1 |